Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
Add more filters










Publication year range
1.
Blood Cancer J ; 7(6): e570, 2017 06 16.
Article in English | MEDLINE | ID: mdl-28622303

ABSTRACT

Bortezomib, in combination with dexamethasone (VD) or with the addition of cyclophosphamide (VCD), is highly effective in patients with amyloid light-chain (AL) amyloidosis. Currently, VCD is considered as a primary regimen for patients with AL, but it is not clear whether the addition of cyclophosphamide to VD further and significantly improves efficacy, given the substantial activity of bortezomib itself. We retrospectively compared the outcomes of 101 patients with AL amyloidosis who received VD (n=59) or VCD (n=42) in two consecutive periods. Early mortality after adjustment for Mayo stage was similar. On intent to treat, a hematologic response rate was 68% for patients treated with VD and 78% for VCD (P=0.26), while complete response+very good partial response (CR+VGPR) rate was 47.5% and 35%, respectively. Higher doses of dexamethasone or twice-weekly bortezomib were not associated with significantly higher CR+VGPR rates. Organ responses occurred in similar rates between the two groups. Median survival was similar (33 vs 36 months, P=0.45) even after adjustment for Mayo stage and dose and schedule of bortezomib and dexamethasone. In conclusion, bortezomib even with low doses of dexamethasone is effective for the treatment of AL amyloidosis; higher doses of dexamethasone and addition of cyclophosphamide do not seem to have a profound effect on efficacy and survival.


Subject(s)
Amyloidosis/drug therapy , Bortezomib/therapeutic use , Cyclophosphamide/therapeutic use , Dexamethasone/therapeutic use , Aged , Amyloidosis/pathology , Antineoplastic Combined Chemotherapy Protocols/pharmacology , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bortezomib/pharmacology , Cyclophosphamide/pharmacology , Dexamethasone/pharmacology , Female , Humans , Male , Middle Aged , Treatment Outcome
3.
Leukemia ; 27(2): 423-9, 2013 Feb.
Article in English | MEDLINE | ID: mdl-22763386

ABSTRACT

The role of thalidomide, bortezomib and lenalidomide in multiple myeloma patients presenting with renal impairment was evaluated in 133 consecutive newly diagnosed patients who were treated with a novel agent-based regimen. A significant improvement of renal function (renalPR (renal partial response)) was observed in 77% of patients treated with bortezomib, in 55% with thalidomide and in 43% with lenalidomide (P=0.011). In multivariate analysis, bortezomib-based therapy was independently associated with a higher probability of renal response compared with thalidomide- or lenalidomide-based therapy. Other important variables included eGFR (estimated glomerular filtration rate) ≥30 ml/min, age ≤65 years and myeloma response. Patients treated with bortezomib achieved at least renalPR in a median of 1.34 months vs 2.7 months for thalidomide and >6 months for lenalidomide-treated patients (P=0.028). In multivariate analysis bortezomib-based therapy, higher doses of dexamethasone (≥160 mg during the first month of treatment), an eGFR ≥30 ml/min and age ≤65 years were independently associated with shorter time to renal response. In conclusion, bortezomib-based therapies may be more appropriate for the initial management of patients with myeloma-related renal failure; however, thalidomide and lenalidomide are also associated with significant probability of improvement of their renal function.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Multiple Myeloma/drug therapy , Renal Insufficiency/drug therapy , Adult , Aged , Aged, 80 and over , Boronic Acids/administration & dosage , Bortezomib , Dexamethasone/administration & dosage , Doxorubicin/administration & dosage , Female , Follow-Up Studies , Glomerular Filtration Rate , Humans , Lenalidomide , Male , Melphalan/administration & dosage , Middle Aged , Multiple Myeloma/complications , Multiple Myeloma/diagnosis , Prednisone/administration & dosage , Prognosis , Pyrazines/administration & dosage , Renal Insufficiency/etiology , Survival Rate , Thalidomide/administration & dosage , Thalidomide/analogs & derivatives , Vincristine/administration & dosage
4.
Artif Organs ; 35(4): 420-5, 2011 Apr.
Article in English | MEDLINE | ID: mdl-20637013

ABSTRACT

Therapy for recurrent focal segmental glomerulosclerosis (FSGS) in the renal allograft is largely based on case reports. The use of plasmapheresis alone (based on its effectiveness in children) appears less effective in adults, reaching a response rate of <40%. Recently, rituximab, an anti-CD20 monoclonal chimeric antibody, showed promising results as rescue therapy in plasmapheresis-resistant recurrent FSGS. However, following rituximab administration, response is variable, often slow and consequently overlooked. We report a series of four cases of recurrent FSGS following renal transplantation successfully treated with a combination of plasmapheresis and rituximab. Complete remission of proteinuria occurred in two and partial remission in the other two patients whereas renal function improved or remained stable. During treatment and the follow-up period (18-60 months) no severe infectious complications were observed. Our data suggest that the combination of plasmapheresis and rituximab is an acceptable treatment in patients with post-transplantation recurrent FSGS.


Subject(s)
Antibodies, Monoclonal, Murine-Derived/therapeutic use , Glomerulosclerosis, Focal Segmental/prevention & control , Glomerulosclerosis, Focal Segmental/therapy , Immunologic Factors/therapeutic use , Kidney Transplantation/adverse effects , Plasmapheresis , Adult , Female , Follow-Up Studies , Glomerulosclerosis, Focal Segmental/drug therapy , Glomerulosclerosis, Focal Segmental/etiology , Humans , Male , Middle Aged , Recurrence , Rituximab , Treatment Outcome
5.
Hippokratia ; 14(3): 215-6, 2010 Jul.
Article in English | MEDLINE | ID: mdl-20981174

ABSTRACT

With the exception of the catastrophic antiphospholipid syndrome (APS), the management of patients with APS has been largely supportive aiming at avoiding a recurrent thrombotic event; it is noteworthy that data concerning therapy targeting the triggering factor (the antiphopsholipid antibodies) are scarce. We report a case of APS manifested as recurrent fetal losses, ischemic stroke and renal dysfunction with concomitant nephrotic syndrome successfully treated with the combination of plasmapheresis and anti-CD20 antibody.

6.
Clin Nephrol ; 72(1): 73-8, 2009 Jul.
Article in English | MEDLINE | ID: mdl-19640391

ABSTRACT

Sunitinib is approved for the treatment of metastatic renal cell carcinoma (RCC). No data are available on sunitinib use specifically in patients with significantly impaired renal function. We evaluated the safety and efficacy of sunitinib in patients with advanced RCC and Grade 4 renal function impairment. Four patients had a calculated creatinine clearance of 15 - 29 ml/min/1.73 m2 prior to initiation of sunitinib. Three patients tolerated treatment well with no renal toxicity: 2 received 17 and 5 cycles of sunitinib at full dose, while 1 received 5 cycles with a dose reduction due to myelotoxicity. We observed one partial response and two patients had stable disease for 24 and 4 months, respectively. The 4th patient had a creatinine clearance of 18 ml/min/1.73 m2 and had treatment discontinued during the first cycle due to poorly controlled hypertension and deterioration of his renal function. We conclude that sunitinib can be administered to the majority of patients with RCC and significant renal function impairment.


Subject(s)
Antineoplastic Agents/therapeutic use , Carcinoma, Renal Cell/drug therapy , Indoles/therapeutic use , Kidney Neoplasms/drug therapy , Pyrroles/therapeutic use , Aged , Carcinoma, Renal Cell/secondary , Carcinoma, Renal Cell/surgery , Combined Modality Therapy , Humans , Kidney Neoplasms/surgery , Liver Neoplasms/drug therapy , Liver Neoplasms/secondary , Male , Nephrectomy , Sunitinib
8.
Transplant Proc ; 36(5): 1413-4, 2004 Jun.
Article in English | MEDLINE | ID: mdl-15251347

ABSTRACT

BK polyoma virus associated nephropathy is increasingly recognized as an important cause of allograft dysfunction among renal transplant recipients. Herein we present the cases of two renal transplant recipients who developed progressive functional deterioration suspicious for BK polyoma virus involvement. One patient had been treated with mycophenolate mofetil (MMF), cyclosporine (CsA), and prednisolone (P), and the second patient with tacrolimus (Tac), MMF, and (P). Using quantitative real-time polymerase chain reactions for BK virus DNA, we monitored the content of BK virus in the blood to evaluate disease progression. The high BK virus load initially detected in the blood samples from these patients decreased in the patient who received MMF, CsA, and P after the reduction of immunosuppression, but not in the patient who was treated with Tac, MMF and P. In contrast to previous reports, our patients had not received treatment with anti-lymphocyte globulin (ALG) or monoclonal anti-CD3 antibody (OKT3) after transplantation. It is concluded that even in the absence of vigorous antirejection treatment, immunosuppressive therapy based on Tac and MMF may carry the risk of BK virus-associated nephropathy. Because BK virus specific antiviral therapy is not available, its course may be monitored by measuring the viral load in blood.


Subject(s)
BK Virus , Immunosuppressive Agents/adverse effects , Kidney Transplantation/adverse effects , Polyomavirus Infections/diagnosis , Adult , BK Virus/isolation & purification , DNA, Viral/blood , Humans , Immunosuppressive Agents/therapeutic use , Male , Middle Aged , Postoperative Complications/virology
10.
Lupus ; 10(9): 606-11, 2001.
Article in English | MEDLINE | ID: mdl-11678448

ABSTRACT

Inducing and maintaining remission in patients with lupus nephritis may be difficult. Current treatments have significant toxicity. Mycophenolate mofetil (MMF) limits damage in murine models of lupus nephritis. We have assessed the efficacy and tolerability of MMF in the treatment of patients with long-standing or resistant lupus nephritis. We have treated 13 patients with biopsy proven lupus nephritis (two membranous nephropathy, four membranous nephropathy with superimposed proliferative changes, seven with proliferative glomerulonephritis). All patients had relapsed on conventional treatment or there were pressing indications to minimise steroid dosage or avoid alkylating agents. Nine out of 13 were treated with MMF and prednisolone, 3/10 with MMF alone and 1/10 with MMF, prednisolone and cyclosporine. Thirteen patients were treated with MMF for up to 37 months (median 25 months). Three patients were withdrawn from MMF during the first 8 months of treatment. The remainder tolerated MMF (median dose 1 g/day). Serological improvements were observed in 9/13 and steroid dosage was reduced in 8/10 patients. Infections occurred in 3/13. One patient relapsed. MMF significantly reduced the rate of decline of renal function. MMF should be considered in the treatment of long-standing or resistant lupus nephritis. Controlled clinical trials are required to confirm these findings.


Subject(s)
Immunosuppressive Agents/administration & dosage , Lupus Nephritis/drug therapy , Mycophenolic Acid/analogs & derivatives , Mycophenolic Acid/administration & dosage , Adrenal Cortex Hormones/administration & dosage , Adult , Blood Pressure , Female , Follow-Up Studies , Humans , Immunosuppressive Agents/adverse effects , Infections , Kidney Failure, Chronic/drug therapy , Kidney Failure, Chronic/microbiology , Lupus Nephritis/microbiology , Middle Aged , Mycophenolic Acid/adverse effects , Patient Dropouts , Pilot Projects , Proteinuria/drug therapy , Proteinuria/microbiology , Severity of Illness Index , Treatment Outcome
11.
Kidney Int Suppl ; 71: S137-40, 1999 Jul.
Article in English | MEDLINE | ID: mdl-10412758

ABSTRACT

BACKGROUND: Our objective was to assess the pro-oxidant status of neoral and tacrolimus in renal transplant patients and monitor the protection provided by vitamin C and vitamin E in normalizing low density lipoprotein (LDL) oxidation lag time of tacrolimus-treated patients. METHODS: Plasma LDL was isolated by density gradient ultracentrifugation from renal transplant patients receiving neoral, tacrolimus and tacrolimus with vitamin C and vitamin E. Oxidation was initiated by the addition of CuCl2 at 37 degrees C and monitored at 234 nm over 480 minutes and oxidation lag time was computed. Total antioxidant capacity of serum was measured using the enhanced chemiluminescent method. RESULTS: LDL from tacrolimus-treated patients had significantly lower oxidation lag time and serum antioxidant activity in comparison with neoral-treated patients, and this was particularly significant during the first four months after transplantation. Vitamin C and E supplementation in tacrolimus treated patients provided protection against oxidation and normalized their oxidation lag time. CONCLUSION: Calcineurin-inhibiting drugs, CsA and tacrolimus, have pro-oxidant activity and they increase the susceptibility of LDL to oxidation. Neoral formulation is fortified with DL-alpha tocopherol and therefore provides protection against oxidation. The present study clearly demonstrates the benefit of giving vitamin C and E supplements to patients taking tacrolimus and this seems to be particularly important during the early period after transplantation.


Subject(s)
Calcineurin Inhibitors , Kidney Transplantation , Lipoproteins, LDL/drug effects , Adult , Ascorbic Acid/therapeutic use , Cholesterol/blood , Cyclosporine/therapeutic use , Drug Therapy, Combination , Female , Humans , Immunosuppressive Agents/therapeutic use , Lipoproteins, LDL/blood , Lipoproteins, LDL/metabolism , Male , Middle Aged , Oxidation-Reduction , Tacrolimus/therapeutic use , Time Factors , Triglycerides/blood , Urea/blood , Vitamin E/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...